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Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation caused by bronchial
alterations, small airways disease and parenchymal destruction. In patients with COPD the structural and functional
lung alterations can progress more or less rapidly from the initial small airways disease to an overt COPD where a
severe expiratory flow limitation takes place. In these conditions, lung hyperinflation develops characterized by
increase in functional residual capacity (FRC) and decrease in inspiratory capacity (IC). Thus, IC is an easy and
reliable index to monitor lung hyperinflation and to assess the efficacy of bronchodilator drugs. When FRC
increases, tidal volume (VT) is located in a more flatted upper part of the P –V curve of the respiratory system and
respiratory muscles must sustain a greater elastic workload. Furthermore, due to inadequate time for expiration,
there is a positive alveolar pressure at the end of expiration (PEEPi). This represents a further elastic workload for the
inspiratory muscles. This impairment of ventilatory mechanics generates dyspnea that in most severely compromised
patients occurs also for small efforts causing activity limitation and worst health-related quality of life (HRQoL). Due
to these respiratory alterations, bronchodilators are the cornerstone of the long-term treatment of COPD in order to
decrease airways resistances, lung hyperinflation and exacerbation rate, and improve patient’s symptoms, exercise
tolerance and health status. Long-acting antimuscarinic bronchodilators (LAMAs) have proven to be very useful in
terms of lung deflation and exercise tolerance. Recently, new LAMAs with several positive characteristics have been
introduced into clinical use among which glycopyrronium bromide has shown to be particularly effective.
Glycopyrronium has a longer-lasting effect compared to other anticholinergic drugs, therefore it allows a single
daily administration and facilitates the therapy of a disease that needs a chronic bronchodilation by decreasing the
mechanic stress of the airways determined by repeated bronchoconstriction and increasing patient’s adherence to
treatment plan with better clinical results. Several studies demonstrated that glycopyrronium is able to positively
and significantly decrease lung hyperinflation, symptoms, and improve psycho-physical status of COPD patients,
with a low rate of adverse events, similar to that of placebo.
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Chronic obstructive pulmonary disease (COPD) is a patho-
logical respiratory condition characterized by persistent
airflow limitation caused in various measures by bronchial
alterations (chronic bronchitis), small airways disease
and parenchymal destruction (pulmonary emphysema).Correspondence: c.sanguinetti@alice.it
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unless otherwise stated.The disease is determined by a chronic abnormal response
to noxious inhaled substances, mainly tobacco smoke,
presents with persistent cough, sputum production, dys-
pnea and decreased exercise tolerance, and is associated
with various complications and comorbidities, especially
cardiovascular and metabolic [1-3]. COPD charges a
relevant social and economic burden, affecting almost
4.5% of population in Italy [1]. The main symptom of
COPD is dyspnea and the patients reduce their daily
activities in an attempt to relieve this symptom; but by
avoiding the physical activity patient enters a vicioustd. This is an Open Access article distributed under the terms of the Creative
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dyspnea.
This article addresses the respiratory alterations occur-
ring in COPD that lead to lung hyperinflation and dys-
pnea, their pathophysiologic and clinical consequences
and the role of bronchodilators with a particular focus
on glycopyrronium at improving health status and health
related quality of life of COPD patients by decreasing
the hyperinflation.
Pathophysiology and consequences of lung
hyperinflation in COPD
The volume of air introduced into the lungs during quiet
breathing (tidal volume, VT) is sufficient for pulmonary
ventilation and gas exchange. The amount of air present
in the lungs at the end of a normal expiration is the
functional residual capacity (FRC) that includes expira-
tory reserve volume (ERV) and residual volume (RV, the
volume of air remaining in the lungs after a deep expir-
ation), which is a result of the force displayed by expira-
tory muscles in the healthy young people to overcome
chest wall elasticity, while in the elderly it increases due
to a reduced elastic force of the lung [4]. At this level,
there is a static equilibrium between the lung and the
chest cage, because the outwards force of chest cage is
completely counterbalanced by the inwards force of pul-
monary elastic recoil and this is defined as relaxation
volume, i.e. the pulmonary pressure equals zero, and
there is no flow through the airways. During exercise or
in other situations when requested, the volume of inspir-
ation increases also utilizing the inspiratory reserve
(IRV) until the total lung capacity (TLC) is reached.
TLC and VC (vital capacity, that is the maximum vol-
ume of air that is possible to mobilize with a deep inspir-
ation followed by a deep expiration) are important
reference indices in diseases causing a restrictive defect,
as pulmonary fibrosis, respiratory muscle disorders, and
chest wall alterations (Figure 1A).
In the volumetric partition of VC [5] particular value
is now attributed to inspiratory capacity (IC, sum of VT
and IRV) because, when reduced, it may testify a condi-
tion of lung hyperinflation (LH), caused by the increase
in RV, FRC, and TLC [6], as frequently observed in
COPD patients [7]. In these patients, IC showed a more
significant correlation with the exercise tolerance than
the forced expiratory volume in one second (FEV1) [8].
In addition, several studies demonstrated that IC, also
when standardized for TLC (IC/TLC), as marker of lung
hyperinflation both in resting conditions (static LH) and
during exercise (dynamic LH),is an independent predict-
ive factor of mortality in COPD patients [9,10], and also
indicative of a longer hospital stay following thoracic
surgery [11]. Therefore, an ideal bronchodilator should
demonstrate to be able to decrease the hyperinflation ofthe patient, increase inspiratory capacity and, conse-
quently, increase exercise tolerance. Based on many
functional and clinical observations, IC, besides FEV1, is
increasingly used as an index to assess the efficacy of
bronchodilator drugs in COPD patients.
Several previous studies [12,13] demonstrated undeni-
ably that the damage caused by the inhalation of toxic
compounds, like cigarette smoke and environmental pol-
lutants, primarily involves the “small airways”. This def-
inition refers to bronchioles with an internal diameter
equal to or lower than two millimeters, that is the ter-
minal and respiratory bronchioles, thus a very peripheral
site in the lung and very close to gas exchanging zone
of pulmonary alveoli [14]. Patency of small airways is
normally maintained, especially in expiration, by the in-
tegrity of bronchial walls that, while lacking in cartilagi-
neous framework, collapse only when the lung empting
is almost complete, and by the alveolar-airways attach-
ments acting as elastic bands to maintain the bronchial
calibre. In smokers, the structural and functional lung
alterations progress more or less rapidly from the initial
small airways disease to an overt COPD [15,16]. At the
beginning of the disease, small airways closure may oc-
casionally occur during tidal expiration, while with the
progression of the disease this alteration is constant and
associated with a severe expiratory flow limitation (EFL)
[17,18]. EFL is caused by the increase in airways resistance
consequence of a reduction of bronchial-bronchiolar cali-
ber due to structural remodeling and augmented vagal
tone, together with the destruction of elastic pulmonary
tissue. The flows normally utilized are thus maximal,that
is the maximum expiratory flow is within the tidal volume
[18], and any further increase in pleural pressure does not
increase the expiratory flow which is only dependent on
the elastic recoil of the lung [19]. Since the elastic recoil
pressure raises in parallel with the increase in lung vol-
ume,when EFL occurs patients must breath at a higher
pulmonary volume to exploit the only mechanism able to
increase their expiratory flow. In these conditions, residual
volume increases due to the closure of the airways at
higher pulmonary volume and consequently FRC in-
creases because the volume at which the balance between
the elastic pressures of the lung and chest wall occurs is
increased, leading, starting from dynamic hyperinflation,
eventually to a static lung hyperinflation (sLH). This has
important implications in that the work of inspiratory
muscles increases to counteract the augmented elasticity
of lung tissue. In addition, the increased pulmonary vol-
ume determines a shortening of the inspiratory muscles
which consequently generate a lower pressure for a certain
stimulus. In the natural history of the anatomic and func-
tional damage of COPD a progressive alteration of pul-
monary volumes occurs characterized by a progressive
increase in FRC and parallel decrease in IC until the
A B
Figure 1 Lung volumes and capacities in normal subjects and in COPD patients. A) Lung volumes and capacities in healthy subject: EELV,
end-expiratory lung volume, ERV, expiratory reserve volume; FRC, functional residual capacity; IC, inspiratory capacity; IRV, inspiratory reserve volume;
RV, residual volume; TLC, total lung capacity; VC, vital capacity; VT, tidal volume. B) Progressive increasing in static lung hyperinflation in relation to
severity of COPD; arrow 1 indicates the threshold of dyspnea onset; arrow 2 indicates the limit of dyspnea tolerance. Modified from [19].
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breathing and it is impossible to increase the extent of
ventilation beyond a certain limit [20] (Figure 1B).
Thus, lung hyperinflation and the consequent alter-
ations of respiratory mechanics determine an increased
respiratory work that in turn leads to fatigue of res-
piratory muscles that must sustain a greater load, with
inefficiency of respiration and onset of respiratory fail-
ure, initially characterized only by hypoxemia and then
also by hypercapnia. Dyspnea usually arises when gas
exchange is inefficient as in ventilation/perfusion mis-
matching, exercise-induced hypoxemia, and impaired
respiratory mechanics, where an uncoupling occurs be-
tween the increased ventilatory stimulus and the de-
creased mechanical performance. In the most severely
compromised COPD patients, dyspnea occurs also for
small efforts and consequently an activity limitation
develops that leads to deconditioning and worsening of
health-related quality of life (HRQoL) [20].
To accomplish a normal expiration and reach the rela-
xation volume, the patient affected by EFL needs longer
expiratory time as the expiratory flow is lower. Therefore,
the inspiration starts at an end-expiratory lung volume
(EELV) greater than the relaxation volume leading to dy-
namic lung hyperinflation (dLH) [21]. Thus, when EFL
arises in COPD patients [22], they breath with progres-
sively increased lung volumes (increased FRC and equally
decreased IC). In this situation the activation of expiratory
muscles, while not increasing the expiratory flow, may ag-
gravate the dyspnea perception by collapsing intrathoracicairways beyond the bronchial closing point [23]. When
EELV increases, normal breathing takes place at a higher
absolute lung volume and VT is situated in a more flatted
upper part of the pressure – volume curve of the re-
spiratory system, such as for its attainment inspiratory
muscles must sustain a greater elastic work. Further-
more, due to inadequate time for expiration, the rela-
xation volume is not reached and the mean alveolar
pressure at the end of expiration exceeds the atmospheric
pressure and has a positive value that is called intrinsic
positive end-expiratory pressure (PEEPi). This represents
a further elastic respiratory load for the inspiratory muscles.
In fact, when inspiration begins inspiratory muscles must
counterbalance this pressure load before generating a nega-
tive alveolar pressure that determines the inspiration and
the achievement of VT. Thus, in COPD patients with dLH,
while inspiratory muscles are able to generate a lower pres-
sure for a given stimulus due to their anatomic and func-
tional change caused by LH, they have to sustain a greater
workload in relation to the increased pulmonary volume at
which VT is fulfilled and to the threshold load charged by
PEEPi [17,18,24,25] (Figure 2). The level of PEEPi has been
found to be correlated with the resting hypercapnia [26].
When these dynamic conditions develop, a rapid increase
in FRC takes place caused by air trapping at the end of ex-
piration and dynamic hyperinflation of the lungs, together
with a parallel decrease in IC, because patients increase the
breathing frequency and further shorten the expiratory
time. In fact, while in the normal subject at the onset of an
exercise there is a fall of EELV, such as the respiratory
Figure 2 Pressure-volume curve of the respiratory system. EELV, end-expiratory lung volume: (1) in healthy subjects, (2) in subjects with lung
hyperinflation; PEEPi, intrinsic end-expiratory positive pressure; VT, tidal volume.
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relationship, and VT increases also utilizing part of the in-
spiratory reserve (IRV), in a subject with EFL and LH tidal
volume cannot be increased beyond a certain level because
any further elevation of pressure cannot generate any
volume increase [18,27]. However, the breathing frequency
is augmented as a compensation attempt, resulting in fur-
ther rise of EELV. In addition, the new positioning of VT
along the pressure-volume curve of the respiratory system
is such that VT lies closer to TLC, and the IRV is
decreased. This is a further limiting factor because the
“dyspnea limit”, that is the volume level at which dyspnea
becomes unbearable, has been shown to be when IRV is
lower than half a litre [28]. Bronchodilators, the cardinal
of COPD therapy, break this vicious circle by reducing
the airway obstruction, which leads to decreasing of the
residual volume allowing patients longer exercise time
which has many beneficial aspects for the patients daily
life and disease progress. A significant correlation also
appeared between the IC decrease and the dyspnea
presence and degree both during exercise testing and
during normal daily activities in COPD patients [29].
Effects of glycopyrronium on lung hyperinflation and its
consequences
Due to persistent airflow limitation in COPD, broncho-
dilators, especially the long-acting ones, are the corner-
stone of the long-term treatment of this disease, with
the aim of decreasing to the minimum the airways resis-
tances and improving the parameters closely correlated
with the patient’s health status and prognosis, like symp-
toms, acute exacerbations, exercise tolerance and phys-
ical and psychic general conditions.
The efficacy of long-acting bronchodilators in COPD
has been extensively documented in studies performedboth with beta2-agonists (LABAs) [30,31] and with mus-
carinic antagonists (LAMAs) [32,33], as the cholinergic
tone is recognized as the major reversible component of
the airflow obstruction in this disease [34]. In almost all
studies the primary outcome measure to assess the drug
efficacy was the FEV1, whose changes however are poorly
correlated with the variations of symptoms and exercise
tolerance, which instead are related to changes of lung
hyperinflation [35,36]. Therefore, in order to assess the ef-
ficacy of a bronchodilator in COPD, the physiologically
more reliable parameter is the inspiratory capacity, which
correlates inversely with FRC and can thus be considered
a marker of changes of LH.
In fact, it has been demonstrated that LH is, at least in
part, reversible with administration of bronchodilators,
and lung deflation causes an increase in IC and symp-
toms improvement in COPD patients. In these patients,
the increase in FEV1 after bronchodilation is generally
small, if any, while the most important effect is the in-
crease in IC, which sustains the symptoms improvement,
even if the indices expressing the rate of bronchial cali-
ber, like the FEV1/FVC ratio, may sometimes be
scarcely improved [37,38]. Noteworthy is the observa-
tion that FRC increases exponentially with the progres-
sive reduction of FEV1 and the most significant change
after bronchodilation is the decrease in FRC and RV,
that is in LH, independently from the basal FEV1 value
[27]. During dynamic conditions it has been also ob-
served that the prolongation of “endurance time” (ET),
i.e. the span of time in which the exercise is tolerated, is
more related to the effect of bronchodilators than other
parameters assessed during cycloergometer exercise or
6 minutes walking test (6MWT) [39]. This means that
bronchodilators decrease directly the hyperinflation and
increase the exercise capacity.
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also with beta2-agonists characterized by a particularly
long duration (lasting 24 hours) of action (“ultra-LABA”)
that allows a single daily administration. In a trial [40]
comparing formoterol and indacaterol the latter at 300
mcg OD provided a greater effect on bronchial obstruc-
tion and LH than the former at usual dose of 12 mcg
BID in patients with COPD. A short-term trial by Rossi
et al. [41] eventually confirmed that indacaterol 150 mcg
OD is capable of increasing IC significantly more than
placebo. In the same study the effect was also numeric-
ally higher than tiotropium bromide (TB) without reach-
ing significance. Interestingly, taking into account the
maximum increase of IC, more patients with indacaterol
exceeded 20% and 30% improvement compared to TB
indicating that indacaterol is capable of producing great
improvements in some patients.
On the other hand, also antimuscarinic bronchodila-
tors have proven to be very useful in terms of lung defla-
tion and exercise tolerance. Recently, new long-acting
LAMAs with several positive characteristics have been
introduced into clinical use among which glycopyrro-
nium has shown to be particularly effective.
Glycopyrronium bromide (GB) has a quaternary am-
monium structure and low oral bioavailability, that re-
duces the drug’s systemic effects [42]. Glycopyrronium is
delivered by a dry-powder inhaler (DPI), the Breezhaler®,
that has a low resistance and requests a lower inspira-
tory flow, thus easy to be utilized by COPD patients of
different age and severity, and already widely used to in-
hale indacaterol dry-powder [43,44].
The longer-lasting effect of GB compared to other
anticholinergic drugs allows a single daily administration,
which can facilitate the therapy of a disease that needs a
chronic bronchodilation by decreasing the mechanic stress
of the airways avoiding repeated bronchoconstriction, and
by increasing patient’s adherence to treatment plan and
thus obtaining better clinical results [45-47].
In a first phase III randomized study [48] of 26 weeks
with 822 patients with moderate-to-severe COPD, effective-
ness, safety and tolerability of GB versus placebo were
assessed. The study demonstrated that glycopyrronium rap-
idly and significantly increased trough FEV1 compared to
placebo on the first day of therapy and remained elevated
for 26 weeks. Mean trough FEV1 at the 12
th week, calcu-
lated as mean of values recorded between 23.15 and 23.45
hours, was significantly (p < 0.001) higher in patients given
GB than in those treated with placebo, and the difference
was 108 ± 14.8 mL, thus greater than the minimum clinic-
ally important difference (MCID) for FEV1 that is 100 mL
[49], reaching 113 ± 16.5 at 26th week. Inspiratory capacity,
an important indicator for hyperinflation, was also signifi-
cantly improved by glycopyrronium reaching a difference
of 104 mL versus placebo already at day 1 and maintainingthis difference over 26 weeks (p < 0.001 vs. placebo in all
cases) [48] (Figure 3), demonstrating that glycopyrronium
is an effective bronchodilator which provides sustainable
bronchodilation and decreases the hyperinflation. As a
consequence of bronchodilation and LH decrease, at the
26th week the dyspnea degree, measured as TDI (Transi-
tional Dyspnea Index) score was significantly (p < 0.001)
improved in COPD patients treated with glycopyrronium
compared to those given placebo, exceeding even the limit
of clinically important difference and suggesting that pa-
tients perceived the improvement. In addition, the rate of
patients treated with GB presenting a clinically significant
improvement of HRQoL measured with the SGRQ (Saint
George’s Respiratory Questionnaire) was greater than that
of patients who took placebo. As already underlined, lung
hyperinflation causes dyspnea and reduces exercise toler-
ance in COPD patients and the increase in IC after GB ad-
ministration is the evidence for the reduction of lung
hyperinflation. The results of this study [48] indicate that
glycopyrronium is capable of positively and significantly
affecting lung hyperinflation, symptoms, and psycho-
physical status of COPD patients, likely allowing them to
better use the tidal volume and improve the respiratory
performance, in presence of a rate of adverse events (AEs)
lower than with placebo.
The favorable results obtained in this study repre-
sented the basis for a second trial [50] whose objective
was to evaluate the efficacy and tolerability of GB, not
only versus placebo but also in relation to TB given
“open-label” for a period of 52 weeks in 1,066 patients
with moderate to severe COPD. GB induced a very fast
bronchodilation within 5 minutes after the first adminis-
tration at the onset of therapy, greater than that caused
by tiotropium and placebo (p < 0.01). At the 26th week,
bronchodilation induced by GB, measured as area under
the curve (AUC) from the administration of the drug
until the 4th hour, was greater than that with TB and pla-
cebo (p < 0.01). Importantly, at the end of first day of
therapy, and at 26th and 52nd week, the difference be-
tween GB and placebo was 91,134, and 108 mL respect-
ively (p < 0.001), approaching rapidly the MCID and
maintaining it over the time, whereas the significant (p <
0.001) difference between tiotropium and placebo was
under the MCID over time (83, 84, and 89 mL respect-
ively). The increase in IC with GB was greater than with
placebo (p < 0.001) and similar to that with TB. Thus, the
results of this second study demonstrated that the adminis-
tration of glycopyrronium was effective on all set end-
points and similar to that of TB, which at that moment was
the only once daily LAMA available for long-term treat-
ment of COPD with inhalant antimuscarinic drugs. How-
ever, GB differed in a greater rapidity of action and higher
bronchodilating effects compared with TB on the first day
of administration, which was maintained at the 12th, 26th,
Figure 3 Difference of inspiratory capacity (IC) values between glycopyrronium bromide and placebo at the end of the first day and at
12th and 26thweek of therapy before the administration of the active drug or placebo. Δ = Difference between glycopyrronium bromide
and placebo.
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ministration of the drug may give the patient the possibil-
ity to carry out the morning activities easier, a period of
the day which is considered the most worrisome by the
majority of patients [51]. The benefit from the fast
bronchodilating effect of GB, which maintains throughout
the time and produces a decrease in lung hyperinflation
and dyspnea, is not only particularly relevant for patients
daily activities, previously limited by LH and its conse-
quences, but it also favours a greater adherence to treat-
ment.The consequences of reduced hyperinflation have
been investigated in another multicentric, cross-over, and
randomized phase III study of 21 days [52], whose main ob-
jective was to assess the effect of GB 50 mcg OD on exer-
cise tolerance in patients with moderate-to-severe COPD,Figure 4 Endurance time (ET) on the first and 21st day of therapy wit
moderate-to-severe COPD. From the data of [52].where the exercise tolerance and inspiratory capacity were
measured as ET during a constant submaximal exercise test
(SMET). Even on the first day, glycopyrronium allowed pa-
tients to tolerate exercise for a longer time than placebo
(the difference was 43.1 seconds more with GB p < 0.001)
and the time difference at the 21st day was further increased
(1 min and 29 sec more with GB, p < 0.001) (Figure 4). The
greater exercise capacity observed in this study with GB ad-
ministration, even in terms of lower muscular exhaustion
during exertion, is really important also because, in rela-
tion to what emerged from other studies [53], patients
can certainly perceive the improvement and become more
active and less detached from the social framework, with
improved quality of life. The increase in exercise tolerance
is mainly caused by the effective and sustainedh glycopyrronium bromide (GB) or placebo in patients with
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which on turn determines a decrease in airways resistance
and lung hyperinflation, in this study witnessed by the sig-
nificant increase in airways conductance and inspiratory
capacity, calculated “isotime” during the exertion in the
course both of GB and of placebo therapy. In fact, the in-
spiratory capacity during GB therapy increased more than
200 mL compared to placebo both at the beginning of the
study and after 3 weeks (Figure 5) (52). This functional
benefit turned into a symptoms improvement, with a
significant and clinically important [54] decrease in dys-
pnea measured with Borg CR10 and TDI scores during
treatment with glycopyrronium compared to placebo.
An increase in IC of 200 mL or more is a remarkable
benefit in patients with seriously limited respiratory
operational volumes, because the elastic charge, and
consequently the effort, is lower during the respiratory
movement (LH decreases and respiratory reserve is
better utilized) and dyspnea level decreases during normal
daily activities. In addition, the incidence of adverse events
(AEs) was similar to that of patients receiving placebo and
the majority of AEs were mild or moderately severe and
no death occurred during the study [52], thus confirming
the safety of glycopyrronium as already demonstrated in
previous studies where also serious AEs (SAEs) occurred
with a lower frequency in the GB group compared with
TB and placebo groups [50].
Quite recently, the results of this study have been con-
firmed by a new evaluation of efficacy and safety of glyco-
pyrronium versus blinded tiotropium [55] in a 12-week
study with 657 patients with moderate-to-severe COPD.
The choice of blinding TB has been taken to minimize
possible sources of bias that could arise in open-label
studies. In fact, patients who know they are given an active
drug or have had previous experience of it may be moreFigure 5 Values of inspiratory capacity (IC) “isotime” during exercise
bromide (GB) or placebo. Modified from [53].prone to report favorable results, or may be influenced on
their decision about remaining on treatment [56]. This
was the first trial where GB has been compared with
blinded TB. Briefly, following the first dose on the 1st
day of treatment GB produced greater FEV1 values than
TB with least squares mean (LSM) differences of 51 mL
and 63 mL compared to TB at 5 min and 15 min post-
dose respectively (both p < 0.001), and FEV1 was greater
with GB than with TB at all time points from 0 to 4
hours post-dose (p < 0.001). Glycopyrronium also deter-
mined a significantly higher increase in inspiratory cap-
acity than tiotropium at 30 min (p < 0.001) and 2 hours
(p < 0.001) after the dose administration indicating to a
higher reduction of hyperinflation. At week 12 FEV1 and
other spirometric variables were comparable between GB
and TB, as well as TDI focal score, SGR total score, inci-
dence of moderate or severe COPD exacerbations, whereas
the mean daily total symptom score was significantly (p =
0.035) lower with GB than with TB. The safety of glycopyr-
ronium was confirmed also in this recent investigation, be-
cause the overall incidence of AEs, SAEs and AEs leading
to discontinuation was low and similar between the two
treatment groups. This study designed to minimize the pos-
sible bias once more demonstrates that in patients with
moderate-to-severe COPD glycopyronium has similar effi-
cacy and safety to tiotropium, but provides a faster onset
of action compared with tiotropium on the first day of
therapy.
Conclusions
Based on the results of the above mentioned studies, glyco-
pyrronium has proven to be capable of inducing favourable
effects on lung hyperinflation and its functional and clinical
consequences. Bronchodilation afforded by glycopyrronium
is more rapid than that of tiotropium since the first dose,on the first and 21th day of therapy with glycopyrronium
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daily dose. This certainly represents an advantage in terms
of adherence to therapy, because it is well known that the
efficacy of a therapy also depends on the patient’s adher-
ence to treatment, that must be agreed by the patient once
the therapeutical plan has been justified and explained in
all details.
Among the crucial factors for adherence, particularly im-
portant are the easiness and reliabity of the device and the
dosing regimen [46], especially for COPD patients who
mostly are old and can present cognitive defects. In fact, in-
correct use of inhalation devices is not rare in COPD and it
may be determined not only by patient-related factors, but
also by the inhaler characteristics and patient’s education
[57-59]. The dose of drug delivered from a DPI depends on
a correct handling of the device, the internal resistance of
the inhaler, and its ability to generate fine particles that can
spread till peripheral airways [60]. In this context the Breez-
haler® appears a very reliable and user-friendly device: be-
sides having a low intrinsic resistance facilitating high
inspiratory flow rates (in excess of 60 L/min) [44], the fine
particle fraction (FPF) generated by Breezhaler® is 26.8% of
the delivered dose versus 9.8% of HandiHaler® (the DPI to
deliver tiotropium) [57] such as the former provides greater
mean intrathoracic drug deposition (31% vs. 22%) and
lower extrathoracic drug deposition (57% vs. 71%) than the
latter. In an open-label, multicenter, two-period, 7-day
crossover study [57] including 82 patients with moderate-
to-severe COPD were assessed the patient’s corrected in-
haler use and the patient’s inhaler preference for Breezhaler®
and Handihaler® relatively to the various steps in use. The
percentage of patients correctly using the inhaler increased
from 1st to 7th day and there was no significant difference
between the two devices. On the contrary, patients
expressed the preference for Breezhaler® in a signi-
ficantly higher percentage compared to Handihaler®
(61% vs. 31% p < 0.01) because of its greater overall com-
fort, simplicity and confidence in use (confidence that in-
halation of drug has been correctly performed).
Semplification of therapeutical regimen by reducing
the number of doses to take led to a greater adherence
to treatment in patients affected with chronic diseases
and mainly with COPD [61,62]. In addition, a lower ad-
herence to treatment has been found to cause a marked
worsening of health status [63], whereas the adherence
to inhalant therapy in COPD is associated with a lower
risk of death and hospitalization for acute exacerbations
[46]. Even the rapidity of action of a drug and the per-
ception of the effect it produces when correctly taken
according to physician’s instructions are important fac-
tors to strengthen the adherence to therapy. In fact, it
has been demonstrated that patients more adherent to
therapy are those who take it correctly, report a substan-
tial improvement due to therapy, and think their doctor isan effective support [64]. Thus, in relation to these issues
glycopyrronium appears particularly reliable due to rapid-
ity of its action, the easiness of inhaler, and the clinically
important long-lasting bronchodilation and symptoms
control it provides.
As to concerns the characteristic of particularly long
bronchodilation afforded by GB, Beeh [45] points out
that, differently from short-acting or twice daily bron-
chodilators, after GB administration there is a marked
increase in AUC 0-24 of FEV1 and an increased value of
trough FEV1 in the morning, that is the worst time of
day for COPD symptoms [51] particularly in patients
with severe disease [65], suggesting that the drug be-
haves like an endobronchial pharmacological stent that
guarantees a continuous patency of the airways. This
can positively affect lung hyperinflation and inspiratory
capacity because it is conceivable that the greater and
persistent bronchodilation, especially at the level of per-
ipheral airways, determines a more complete pulmonary
empting during tidal breathing and improves the respira-
tory mechanics, with consequent decrease in dyspnea
and increase in exercise capacity. Such effect has been
assimilated to that induced by surgical reduction of lung
volume that is successfully performed in patients with
upper lobes emphysema (pharmacological lung volume
reduction).
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